Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
03 Agosto 2023 - 7:00AM
Immunocore to report second quarter
2023 financial results and host
call on August 10, 2023
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& ROCKVILLE, Md., US, 03 August 2023) Immunocore Holdings Plc
(Nasdaq: IMCR), a commercial-stage biotechnology company pioneering
the development of a novel class of T cell receptor (TCR)
bispecific immunotherapies designed to treat a broad range of
diseases, including cancer, infectious diseases and autoimmune
conditions, today announced that it will report second quarter
financial results, before the US markets open on Thursday, August
10, 2023. Following the announcement, the Company will host a live
teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to
discuss their financial results and provide a business and
portfolio update.
Audio WebcastThe call will be
webcast live and can be accessed by visiting ‘Events’, under ‘News
& Events’, via the ‘Investors’ section of Immunocore’s website
at www.immunocore.com. Following the event, a replay will also be
made available for a limited time.
Conference Call
Details:Domestic (toll-free): 877-405-1239International
(toll): +1 201-389-0851
##
About
Immunocore
Immunocore is a commercial-stage biotechnology company
pioneering the development of a novel class of TCR bispecific
immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs
Against X disease – designed to treat a broad range of diseases,
including cancer, autoimmune, and infectious disease. Leveraging
its proprietary, flexible, off-the-shelf ImmTAX platform,
Immunocore is developing a deep pipeline in multiple therapeutic
areas, including five clinical stage programs in oncology and
infectious disease, advanced pre-clinical programs in autoimmune
disease and multiple earlier pre-clinical programs. Immunocore’s
most advanced oncology TCR therapeutic, KIMMTRAK has been approved
for the treatment of HLA-A*02:01-positive adult patients with
unresectable or metastatic uveal melanoma in the United States,
European Union, Canada, Australia, and the United Kingdom.
CONTACT:
Immunocore Sébastien Desprez, Head of
CommunicationsT: +44 (0) 7458030732E:
sebastien.desprez@immunocore.comFollow on Twitter: @Immunocore
Investor Relations Clayton Robertson,
Head of Investor RelationsT: +1 215-384-4781E:
ir@immunocore.com
Immunocore (NASDAQ:IMCR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Immunocore (NASDAQ:IMCR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024